Bliss GVS Pharma has informed that the meeting of the Board of Directors of the Company is scheduled on 03/08/2022, to consider and approve the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30, 2022. Further, pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015 and Company's Code of Internal Procedures and Conduct for Regulating, Monitoring and Reporting of Trading by Designated Persons, the trading window for dealing in shares of the Company was closed for all the Designated Persons and their immediate relatives of the Company from July 01, 2022 and shall remain closed till 48 hours after the announcement/declaration of Unaudited Financial Results of the Company for the quarter ended June 30, 2022.
The above information is a part of company’s filings submitted to BSE.
